Carisma Therapeutics, Inc. is a pharmaceutical company in the United States that specializes in developing innovative immunotherapies for cancer and other diseases using their proprietary ESG cell engineering platform. With a medium risk rating score of 26.2, Carisma Therapeutics is focused on utilizing engineered macrophages and monocytes to create transformative treatments. Their comprehensive cell therapy platform harnesses the power of myeloid cells to target and treat serious illnesses.